Sensitivity and discriminatory ability of the ankylosing spondylitis disease activity score in patients treated with etanercept or sulphasalazine in the ascend trial

Rheumatology (United Kingdom)

Volumn 51, Issue 10, 2012, Pages 1894-1905

  Van der heijde, Désirée ^a   Braun, Jürgen ^b   Dougados, Maxime ^c   Sieper, Joachim ^d   Pedersen, Ronald ^e   Szumski, Annette ^e   Koenig, Andrew S ^e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Cochin Hospital ^*  (France)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e PFIZER INC   (United States)

Author keywords

Ankylosing spondylitis; ASAS; ASDAS; BASDAI; C reactive protein; Etanercept; Sulphasalazine; TNF inhibitor

Indexed keywords

CORTICOSTEROID; ETANERCEPT; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTHRITIS; ARTICLE; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PERIPHERAL ARTHRITIS; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM;

ADULT; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; SULFASALAZINE; TREATMENT OUTCOME;

EID: 84867135772     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes142     Document Type: Article

References (15)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369:1379-90.
2. Davis JC, Van der Heijde D, Dougados M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005;53:494-501.
3. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis -results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000;27:613-22.
4. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42:2325-9.
5. Zochling J, Van der Heijde D, Burgos-Vargas R et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
6. Brandt J, Khariouzov A, Listing J et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
7. Davis JC Jr, Van der Heijde DM, Braun J et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67: 346-52.
8. Dijkmans B, Emery P, Hakala M et al. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009;36:1256-64.
9. Martin-Mola E, Sieper J, Leirisalo-Repo M et al. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28: 238-45.
10. Van der Heijde D, Lie E, Kvien TK et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:1811-8.
11. Machado P, Landewe R, Lie E et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53.
12. Braun J, Van der Horst-Bruinsma IE, Huang F et al. Clinical efficacy and safety of etanercept versus sulfasalazine in ankylosing spondylitis patients: a randomized, double-blind study (ASCEND Trial). Arthritis Rheum 2010, doi: 2010.1002/art.30223.
13. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
14. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21: 2286-91.
15. Pedersen SJ, Sorensen IJ, Garnero P et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis 2011;70: 1375-81.